Conference Day One

8:00 am Check-In & Light Breakfast

8:50 am Chair’s Opening Remarks

• Venkata Krishnamurthy Senior Vice President & Head of Platform & RNA Editing, Korro Bio

Uncovering RNA Editing’s Position in the Market to Improve Investment for more Effective Commercial Growth

9:00 am Reviewing RNA Editing Market Landscape

• Steve Seedhouse Managing Director, Biotechnology Equity Research Analyst, Raymond James

9:15 am Fireside Chat: Discussing Investment with Investors to Better Understand their Views for Advancement of RNA Editing Therapies

• Andrew Fraley CTO, Judo Bio, Atlas Venture
• Steve Seedhouse Managing Director, Biotechnology Equity Research Analyst, Raymond James

10:15 am Morning Break & Speed Networking

Uncovering RNA Editing’s Capability for Evolving a Wider Genetic Disease Landscape to Enhance the Treatable Patient Population via RNA Editing Drugs

11:15 am Roundtable Discussion: Standing Out from the Crowd: Understanding RNA Editing’s Unique Potential for Successful Treatment of More Diseases

• Mao Taketani Director, Synthetic Biology, Jorna Therapeutics

12:15 pm Lunch & Networking

1:30 pm XNA-Hub: The First Worldwide Experimentally-Calibrated in-silico Platform to Model & Investigate Natural & Non-Natural Nucleic Acids.

• Vito Genna Director - Nucleic Acid, Nostrum Biodiscovery - NBD

1:45 pm Generative Machine Learning Models to Engineer ADAR dsRNA Substrates for Efficient & Selective A-to-I RNA Editing

• Lina Bagepalli Scientist II, Shape Therapeutics

Accomplishing Improved RNA Editing by Harnessing Innovative Screening Methods to Detect Effective Guide RNAs

2:15 pm Developing Screening Strategies to Identify the Most Effective LEAPER arRNA for More Efficacious RNA Editing Therapies

• Pengfei Yuan Chief Technology Officer, EdiGene

2:45 pm Afternoon Break & Scientific Poster Session

3:45 pm Multi-kilobase RNA edits with Splice Editors

• Jacob Borrajo, PhD Co-Founder & Chief executive officer, Amber Bio

Taking Advantage of RNA Trans-Splicing for More Efficient Editing of Alternative Targets to Widen the Disease Landscape

4:15 pm Advantages of RNA Trans-splicing for Editing Inherited & Acquired Mutations that Cause Disease

• C. Anthony Altar, PhD President and Chief Operating Officer, Splice Therapeutics

4:45 pm Chair’s Closing Remarks & End of Conference Day One

• Venkata Krishnamurthy Senior Vice President & Head of Platform & RNA Editing, Korro Bio